According to Fortune Business Insights, the global drug discovery services market size was valued at USD 19.76 billion in 2025 and is projected to grow from USD 21.11 billion in 2026 to USD 36.22 billion by 2034, exhibiting a CAGR of 7.0% during the forecast period. North America dominated the drug discovery services market with a market share of 39.62% in 2025.
The market is gaining importance as pharmaceutical and biotechnology companies increasingly rely on specialized research services to accelerate the development of new medicines, improve research efficiency, and address complex therapeutic challenges. Drug discovery services support the identification, validation, and development of potential drug candidates through scientific expertise, advanced technologies, and integrated research capabilities. The growing complexity of drug development and the need to optimize research activities are encouraging companies to collaborate with specialized service providers.
Continue reading for more details:
https://www.fortunebusinessinsights.com/drug-discovery-services-market-117651
The drug discovery services market is segmented by service type, discovery phase, drug type, therapeutic area, and end user. Based on service type, the market is divided into chemistry services and biology services. Chemistry services include synthetic chemistry services, analytical chemistry services, and other services. Chemistry services account for a significant portion of market demand because they support the identification, synthesis, and optimization of chemical compounds used in drug development. Pharmaceutical and biotechnology companies increasingly outsource these activities to specialized service providers to improve research efficiency and access advanced laboratory capabilities. Biology services include in-vitro profiling services, toxicology services, and other services. The biology services segment is expected to experience strong growth as researchers increasingly require biological testing, toxicity assessment, and specialized profiling to evaluate potential drug candidates.
Based on discovery phase, the market is categorized into target identification and validation, hit identification, hit-to-lead, lead optimization, and others. Lead optimization represents a significant segment because it helps researchers improve the effectiveness, safety, and characteristics of potential drug candidates before further development. Target identification and validation are also important as they enable researchers to identify suitable biological targets associated with diseases. Based on drug type, the market is divided into small molecules and biologics. Small molecules hold a prominent position because of their extensive applications across therapeutic areas, while biologics are gaining attention due to advancements in biotechnology and the increasing development of targeted treatments. By therapeutic area, the market is categorized into oncology, neurological diseases, infectious diseases, cardiovascular diseases, and others. Oncology represents a major application area due to the growing need for innovative cancer treatments. Based on end user, the market is segmented into pharmaceutical and biotechnological companies, academic and research institutes, and others. Pharmaceutical and biotechnological companies represent an important customer group because of their extensive research requirements and growing dependence on outsourced drug discovery activities.